title: Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies.
abstract: OBJECTIVE
  To compare the therapeutic efficacy and safety of ivermectin and lindane for the treatment of human scabies.
  
  
  METHODS
  Randomized, prospective, controlled, double-blind, "double-dummy," and parallel clinical study.
  
  
  METHODS
  A single department of dermatology at a hospital in Buenos Aires, Argentina.
  
  
  METHODS
  Patients were outpatients, hospitalized patients, and those referred to our hospital from nursing homes and asylums. Fifty-three patients had clinical signs and symptoms compatible with scabies.
  
  
  METHODS
  Patients received either a single oral dose of ivermectin (150-200 microg/kg of body weight) or a topical application of 1% lindane solution. Treatment was repeated after 15 days if clinical cure had not occurred.
  
  
  METHODS
  Clinical healing and adverse effects.
  
  
  RESULTS
  Of 53 patients, 43 (81%) completed the study, 19 in the group treated with ivermectin and 24 in the group treated with lindane. At day 15, 14 patients (74%; 95% confidence interval, 48.8%-90.8%) in the group receiving ivermectin showed healing of their scabies and 13 patients (54%; 95% confidence interval, 32.8%-74.4%) in the group treated with lindane were healed. At 29 days, both treatments resulted in statistically equivalent therapeutic efficacy: 18 patients (95%; 95% confidence interval, 74.0%-99.9%) were healed with ivermectin and 23 patients (96%; 95% confidence interval, 78.9%, 99.9%) were healed with lindane (P<.02). Adverse effects from the treatments were few, mild, and transient. Results from laboratory tests showed no major abnormalities and no difference between treatments.
  
  
  CONCLUSIONS
  Ivermectin is as effective as lindane for the treatment of scabies. Ivermectin is simpler to use and, therefore, is a promising tool to improve compliance and to control infestations.
authors.affiliation: Department of Dermatology, the Hospital General de Agudos Dr Cosme Argerich, Buenos Aires, Argentina. chouela@impsat1.com.ar
authors.forename: E N
authors.initials: EN
authors.lastname: Chouela
authors.forename: A M
authors.initials: AM
authors.lastname: Abeldaño
authors.forename: G
authors.initials: G
authors.lastname: Pellerano
authors.forename: M
authors.initials: M
authors.lastname: La Forgia
authors.forename: R M
authors.initials: RM
authors.lastname: Papale
authors.forename: A
authors.initials: A
authors.lastname: Garsd
authors.forename: M C
authors.initials: MC
authors.lastname: Balian
authors.forename: V
authors.initials: V
authors.lastname: Battista
authors.forename: N
authors.initials: N
authors.lastname: Poggio
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D001556:Hexachlorocyclohexane / Q000627:therapeutic use*; D006801:Humans; D007306:Insecticides / Q000627:therapeutic use*; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D012532:Scabies / Q000188:drug therapy*
chemical_list: D007306:Insecticides; D001556:Hexachlorocyclohexane; D007559:Ivermectin